[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"angiokeratomas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:angiokeratomas":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100635391","phase-2-a-phase-2-baseline-controlled-study-evaluating-the-safety-and-efficacy-of-ptx-022-sirolimus-topical-gel-39-in-the-treatment-of-angiokeratomas-lotu-100635391",false,"NCT07552077","A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)","LOTU","Inclusion Criteria:\n\n* Participants must be 6 years or older\n* Diagnosed with angiokeratoma\n* Able and willing to comply with all protocol-related activities\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Any significant concurrent condition that could adversely affect participation\n* Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications or to PTX-022\n* Patients deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities","ALL","6 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas",[26],"Angiokeratomas",[28],"angiokeratoma","RECRUITING","2026-04-20",{"date":32,"type":33},"2026-04-27","ACTUAL",{"date":35,"type":20},"2026-04",{"date":37,"type":20},"2027-09",{"name":39,"class":40},"Palvella Therapeutics, Inc.","INDUSTRY",4]